Attention Pharmacists and Pharmacy Techs: Click to access CPE Monitor and CE information More Information
This activity will review the latest PK recommendations for Factor VIII and IX replacement and how to use and interpret PK parameters to assess treatment plans.
Choose from the criteria below to find an activity that fits you best.
|A product of the Society of Infectious Diseases Pharmacists Education Center (SIDPEC)|
Note: If you attended the live CE activity titled "Emerging Infections from A to Zika?" at the ASM Microbe Meeting on June 1, 2017 in New Orleans, Louisiana AND received CE credit (i.e. a pharmacist CE statement of credit with ACPE UAN 0072-9999-17-018-L01-P), you are ineligible to also receive credit for this home-study on-demand web activity.
Recently identified pathogens and the development of resistance with current pathogens
is changing the infection threat level to patients. This activity will explore some
of the emerging infections and look at the threat levels in the United States. Some
of the topics addressed include Ebola, Zika, Legionella, Influenza A, resistance,
and other pathogens. The role of the Pharmacist as a member of the multidisciplinary
team in this battle will also be discussed.
This is a featured CE activity on the Society of Infectious Diseases Pharmacists Education Center (SIDPEC) website. SIDPEC is the educational hub of the Society of Infectious Diseases Pharmacists (SIDP). The SIDPEC portal provides educational activities on infectious disease pharmacotherapy for clinical pharmacists, health‐systems pharmacists, community pharmacists, and other allied‐health disciplines.
At the conclusion of this activity, participants should be able to:
Scott Fridkin, MD
Professor of Medicine
Emory University School of Medicine
Professor of Epidemiology
Rollins School of Public Health
No commercial funding was received for this activity.
Release Date: 6-1-2017
Expiration Date: 6-15-2019
This CE activity is jointly provided by West Virginia University School of Pharmacy (WVUSoP), ProCE, Inc. and SIDP. West Virginia University School of Pharmacy is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. ACPE Universal Activity Number 0072-9999-17-018-H01-P has been assigned to this knowledge-based home-study CE activity (initial release date 6-1-2017). This CE activity is approved for 1.0 contact hour (1.0 CEU) in states that recognize ACPE providers. This CE activity is provided at no cost to participants. Completion of an evaluation and post-test with a score of 70% or higher is required to receive CE credit. CE credit will be uploaded to NABP/CPE Monitor. No partial credit will be given.
It is the policy of ProCE, Inc. to ensure balance, independence, objectivity and
scientific rigor in all of its continuing education activities. Faculty must disclose
to participants any significant financial interest or affiliation with companies that
manufacture or market products discussed in this activity. Dr. Fridkin has served
as an Advisor for Pfizer.
Please note: The information and views presented in this activity are those of the faculty through clinical practice and knowledge of the professional literature. Portions of this activity may include the use of drugs and/or devices for unlabeled indications, which should be considered experimental. Participants are advised to consult manufacturer product information and the professional literature, and use professional judgment in applying the presented information in patient-care activities.
The material presented in this CE activity does not reflect the views of ProCE, Inc. or the commercial sponsor. These materials may discuss uses and dosages for therapeutic products, processes, procedures and inferred diagnoses that have not been approved by the United States Food and Drug Administration. A qualified health care professional should be consulted before using any therapeutic product discussed. All readers and continuing education participants should verify all information and data before treating patients or employing any therapies described in this continuing education activity.